Bochenek Tomasz, Lelek Michał, Kowal-Kałamajka Małgorzata, Kusz Błażej, Szczogiel Jan, Jaklik Andrzej, Roleder Tomasz, Mizia-Stec Katarzyna
First Department of Cardiology, Medical University of Silesia, Katowice, Poland.
Regional Specialist Hospital, Research and Development Center, Wroclaw, Poland.
Postepy Kardiol Interwencyjnej. 2020 Jun;16(2):138-144. doi: 10.5114/aic.2020.96056. Epub 2020 Jun 23.
Radial access reduces the number of vascular complications. Radial artery spasm (RAS) can be prevented by the use of spasmolytic agents. However, use of these drugs can be possibly limited to certain groups of patients.
To assess the feasibility and safety of coronary angiography and percutaneous coronary interventions through the radial artery without the routine use of spasmolytic agents.
A group of 293 patients (M/F 180/113, mean age: 67 ±10 years) who underwent coronary angiography and interventions through the radial artery approach was studied. Spasmolytic agents were applied in case of RAS. Every patient had ultrasound assessment of the radial artery on the next day to assess its diameter and detect occlusion.
RAS was observed in 55 patients (18.8%, M/F 28/27) and radial artery occlusion (RAO) in 47 (16%, M/F: 24/23) cases. RAS was followed by RAO in 17 cases, which constituted 17/55 (30.9%) of all RAS. Two patients had symptomatic occlusion, which required prolonged anticoagulation with complete restoration of patency. The RAS was higher in prolonged procedures (angiography time 32.6 ±12.8 vs. 29 ±13.5 min, = 0.03; intervention time 40 ±23.5 vs. 26.3 ±25 min, = 0.0035) and was dependent on time of the local pressure (7.5 ±2.3 vs. 6.5 ±2.8 h, = 0.03). The RAO increased proportionally to the number of catheters used ( = 0.01) and was dependent on time of the local pressure (8.6 ±3.5 vs. 6.4 ±2.7 h, < 0.001).
Our study showed that angiography and interventions without routine use of spasmolytic agents were feasible and safe. RAS and RAO are related to independent risk factors and comparable to data from the literature when spasmolytics were used.
桡动脉入路可减少血管并发症的发生。使用解痉药物可预防桡动脉痉挛(RAS)。然而,这些药物的使用可能仅限于某些特定患者群体。
评估在不常规使用解痉药物的情况下,经桡动脉进行冠状动脉造影和经皮冠状动脉介入治疗的可行性和安全性。
对一组293例经桡动脉入路进行冠状动脉造影和介入治疗的患者(男/女:180/113,平均年龄:67±10岁)进行研究。发生RAS时应用解痉药物。每位患者在次日接受桡动脉超声评估,以评估其直径并检测是否闭塞。
55例患者(18.8%,男/女:28/27)出现RAS,47例(16%,男/女:24/23)出现桡动脉闭塞(RAO)。17例患者RAS后发生RAO,占所有RAS的17/55(30.9%)。2例患者出现有症状的闭塞,需要延长抗凝治疗以使血管完全再通。长时间操作时RAS发生率更高(造影时间32.6±12.8 vs. 29±13.5分钟,P = 0.03;介入时间40±23.5 vs. 26.3±25分钟,P = 0.0035),且与局部压迫时间有关(7.5±2.3 vs. 6.5±2.8小时,P = 0.03)。RAO与所用导管数量成正比(P = 0.01),且与局部压迫时间有关(8.6±3.5 vs. 6.4±2.7小时,P < 0.001)。
我们的研究表明,不常规使用解痉药物进行造影和介入治疗是可行且安全的。RAS和RAO与独立危险因素相关,与使用解痉药物时的文献数据相当。